Covenant Asset Management’s Biogen BIIB Stock Holding History

Covenant Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,000	Closed	-$890K	–	141
2019 Q4	$890K	Buy	+3,000	New	+$832K	0.39%	76

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Covenant Asset Management's BIIB Position: Q4 2021 in Review

Covenant Asset Management sold out of Biogen (BIIB) in Q4 2021, closing a stake of 794 shares — an estimated $225K sold.

Covenant Asset Management first reported a position in BIIB in Q4 2016 and held it in 19 quarters. The position peaked at $3.64M in Q4 2016. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Covenant Asset Management reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Covenant Asset Management sold 794 Biogen shares in Q4 2021, an estimated $225K.
Covenant Asset Management first reported a position in Biogen in Q4 2016 and held it in 19 quarters.
Covenant Asset Management's Biogen position peaked at $3.64M in Q4 2016.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Covenant Asset Management's 13F filing for Q4 2021, filed 26 Jan 2022.